Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EPS (Basic) (2021 - 2025)

Verrica Pharmaceuticals has reported EPS (Basic) over the past 5 years, most recently at -$0.65 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.65 for Q4 2025, up 64.29% from a year ago — trailing twelve months through Dec 2025 was -$0.76 (up 92.99% YoY), and the annual figure for FY2025 was -$1.68, up 88.63%.
  • EPS (Basic) for Q4 2025 was -$0.65 at Verrica Pharmaceuticals, down from -$0.03 in the prior quarter.
  • Over the last five years, EPS (Basic) for VRCA hit a ceiling of $0.02 in Q2 2025 and a floor of -$4.88 in Q3 2024.
  • Median EPS (Basic) over the past 5 years was -$0.36 (2021), compared with a mean of -$0.76.
  • Biggest five-year swings in EPS (Basic): tumbled 26322.48% in 2023 and later soared 100.54% in 2025.
  • Verrica Pharmaceuticals' EPS (Basic) stood at -$0.35 in 2021, then skyrocketed by 60.0% to -$0.14 in 2022, then tumbled by 285.71% to -$0.54 in 2023, then crashed by 237.04% to -$1.82 in 2024, then surged by 64.29% to -$0.65 in 2025.
  • The last three reported values for EPS (Basic) were -$0.65 (Q4 2025), -$0.03 (Q3 2025), and $0.02 (Q2 2025) per Business Quant data.